...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical obesity. >Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
【24h】

Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.

机译：预测的响应与减肥glucagon-like peptide-1受体激动剂治疗严重肥胖的青少年。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In two previous, separate clinical trials, we demonstrated significant reductions in body mass index (BMI) with exenatide in adolescents with severe obesity. In the present study, we pooled data from these near identical trials to evaluate factors that may predict BMI reduction at 3 months. Data from 32 patients (mean age 14.3?±?2.2 years; 69% female; mean BMI 39.8?±?5.8?kg?m(-2)) were included. Exenatide treatment consisted of 5?mcg twice daily for 1 month, followed by an increase to 10?mcg twice daily for 2 additional months. Predictor variables included baseline BMI, BMI percent change at 1 month, incidence of nausea or vomiting and baseline appetite and satiety measures. Treatment effects of percent change in BMI from baseline were estimated within predictor subgroups using generalized estimating equations with exchangeable working correlation and robust variance estimation for confidence intervals and P-values to account for paired observations. The pooled data treatment effect on absolute BMI at 3 months was -3.42% (95% confidence interval: -5.41%, -1.42%) compared to placebo. Within treated participants, appetite at baseline (treatment effect in high [-4.28%] vs. low [1.02%], P?=?0.028) and sex (treatment effect in female [-4.78%] vs. male [0.76%], P?=?0.007) were significant predictors of change in BMI at 3 months. Baseline BMI, BMI percent change at 1 month, age, incidence of nausea, vomiting, or other gastrointestinal symptoms and satiety scores did not predict 3-month responses. Sex and measures of appetite may serve as useful predictors of glucagon-like peptide-1 receptor agonist treatment response among adolescents with severe obesity.
机译：在前两次,独立的临床试验,我们体重显著减少指数(BMI)与exenatide青少年严重肥胖。附近的数据从这些相同的试验评估因素可能在3预测体重指数降低个月。±14.3 ? 2.2年;±39.8 ? 5.8公斤? m(2))。治疗包括5 ?月,紧随其后的是一个增加到10 ?每天额外2个月。变量包括基线BMI、BMI百分比在1月,恶心或发病率呕吐和基线食欲和饱腹感措施。BMI从基线估计在预测子组使用广义估计方程可交换的相关工作和鲁棒性置信区间和方差估计假定值占成对观测。集中数据处理效果绝对BMI在3个月为-3.42%(95%置信区间:-5.41%、-1.42%)与安慰剂相比。治疗的参与者,在基线需求(高(-4.28%)和低的治疗效果0.028 (1.02%), P = ?)和性(治疗效果女性(-4.78%)比男性(0.76%),P ? = ? 0.007)改变体重指数在3的重要预测因子个月。月,年龄的增长,发病率的恶心、呕吐、或其他胃肠道症状和饱腹感分数没有预测三个月反应。需求可以作为有用的措施预测glucagon-like peptide-1受体受体激动剂治疗反应青少年严重肥胖。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号